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Abstract
Background: Epithelial to mesenchymal transition (EMT) occurs during cancer cell invasion and malignant
metastasis. Features of EMT include spindle-like cell morphology, loss of epithelial cellular markers and gain of
mesenchymal phenotype. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein (MSP)
has been implicated in cellular EMT program; however, the major signaling determinant(s) responsible for MSP-
induced EMT is unknown.
Results: The study presented here demonstrates that RSK2, a downstream signaling protein of the Ras-Erk1/2
pathway, is the principal molecule that links MSP-activated RON signaling to complete EMT. Using MDCK cells
expressing RON as a model, a spindle-shape based screen was conducted, which identifies RSK2 among various
intracellular proteins as a potential signaling molecule responsible for MSP-induced EMT. MSP stimulation
dissociated RSK2 with Erk1/2 and promoted RSK2 nuclear translocation. MSP strongly induced RSK2
phosphorylation in a dose-dependent manner. These effects relied on RON and Erk1/2 phosphorylation, which is
significantly potentiated by transforming growth factor (TGF)-b1, an EMT-inducing cytokine. Specific RSK inhibitor
SL0101 completely prevented MSP-induced RSK phosphorylation, which results in inhibition of MSP-induced
spindle-like morphology and suppression of cell migration associated with EMT. In HT-29 cancer cells that barely
express RSK2, forced RSK2 expression results in EMT-like phenotype upon MSP stimulation. Moreover, specific
siRNA-mediated silencing of RSK2 but not RSK1 in L3.6pl pancreatic cancer cells significantly inhibited MSP-induced
EMT-like phenotype and cell migration.
Conclusions: MSP-induced RSK2 activation is a critical determinant linking RON signaling to cellular EMT program.
Inhibition of RSK2 activity may provide a therapeutic opportunity for blocking RON-mediated cancer cell migration
and subsequent invasion.
Background
Epithelial to mesenchymal transition (EMT) is a biologi-
cal process in polarized epithelial cells, which occurs in
various physiological and pathological conditions [1].
Complete EMT is characterized by spindle-like cell
morphology, loss of epithelial cellular markers such as
E-cadherin, and gain of mesenchymal phenotype by
expressing filament proteins including vimentin and
a-smooth muscle actin [1,2]. Cells undergoing EMT are
highly mobile and invasive [2,3]. During embryonic
development, EMT enables cells to migrate or invade
into neighboring tissues and maturate or differentiate
into specialized cells [1,2]. In epithelial malignant pro-
gression, EMT has emerged as a critical player in regu-
lating cancer cell invasive phenotype [4,5]. Acquiring
EMT is a critical step for cancer cells to dissociate from
a primary tumor mass and subsequently migrate and
invade adjacent tissues for remote metastasis [4,5].
Recently, EMT has been linked with cancer stem-like
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phenotype in certain epithelia tumors [6,7]. As demon-
strated, breast cancer cells express several cellular mar-
kers that resemble the stem-like phenotype during their
progression towards EMT [6,7]. These observations
highlight the importance of cellular EMT program in
tumorigenic progression of cancer cells.
Development of EMT in cancer cells is regulated and
precisely controlled at different cellular levels [4,5]. Var-
ious proteins such as receptor tyrosine kinases (RTK)
[8-10], cytokine receptors [11,12], intracellular signaling
molecules [13,14], and transcriptional factors [15,16] are
involved in cellular EMT program. At the signaling
level, RTK-mediated activation of extracellular signal-
regulated kinase (Erk1/2) has been implicated as a
critical pathway for initiation of EMT [13,17,18]. Trans-
forming growth factor (TGF)-b1-stimulated TGF-b
receptor I/II and Smad signaling also play a pivotal role
in induction of EMT [11,19]. Additional pathways such
as Wnt-b-catenin signaling also have been implicated in
EMT [20]. Convincing evidence indicates that signals
coordinated among different pathways such as the RTK-
Erk1/2 and TGF-b1-Smad pathways maximize trans-
differentiation of epithelial tumor cells towards EMT
[1,2]. Moreover, such coordination raises the possibility
that a converging signal for diverse pathways may exist,
and may act as a central determinant controlling cellular
EMT program.
Human 90 kDa ribosomal S6 kinases (RSK) belong to
a family of Ser/Thr kinases with two unique functional
kinase domains [21]. The family consists of four iso-
forms (RSK1-4), of which RSK1 and RSK2 are currently
under intensive investigation for their roles in cellular
signaling [21-23]. In quiescent cells, RSK forms a pro-
tein-protein complex with Erk1/2 [24] and is considered
to be a downstream signaling molecule of the Ras-Erk1/
2 pathway [21]. Activation of RSK is featured by phos-
phorylation, dissociation from Erk1/2, and subsequent
nuclear translocation [21]. Various extracellular factors
including growth factors, cytokines, chemokines, peptide
hormones, and neurotransmitters are known to directly
activate RSK [21]. RSK phosphorylation occurs at multi-
ple Ser and Thr residues through sequential steps by
various kinases such as Erk1/2 [21-24]. Activated RSK
phosphorylates many cytosolic and nuclear targets such
as FLNA, BAD, DAPK, p27KIP1, and transcription fac-
tors including CREB, NF-B, and NFAT3 [21-25].
Recently, RSK has emerged as a major player in the con-
trol of epithelial cell phenotype and motility [22]. RSK is
indicated as a principal effector of the Ras-Erk1/2 path-
way for eliciting a coordinated promotile/invasive
program and phenotype in epithelial cells [22]. A gen-
ome-wide RNAi screen also has found that multiple
proteins in various pathways depend on RSK for cellular
migration [23]. These discoveries indicate that activation
of RSK could be an essential convergent point for regu-
lating cellular phenotypic changes and motile/invasive
activities.
The present study sought to identify the major signal-
ing molecule(s) responsible for EMT induced by macro-
phage-stimulating protein (MSP) [26], also known as
hepatocyte growth factor (HGF)-like protein [27]. MSP
is a serum-derived growth factor that specifically binds
and activates the RON receptor tyrosine kinase [28,29],
a member of the MET proto-oncogene family [27]. Pre-
vious studies have observed that RON-mediated activa-
tion of the Ras-Erk1/2 pathway is critically important in
transducing signals leading to EMT [30,31]. However,
the downstream signaling molecule(s) that controls
RON-mediated EMT is unknown. To facilitate this
study, Martin-Darby canine kidney (MDCK) cells
expressing human RON, which is known to show com-
plete EMT [30,31] was used as a model and a cell-shape
based screen using various small chemical inhibitors was
applied. By analyzing potential signaling proteins that
are involved in MSP-induced EMT-like activities, we
discovered that RSK2 is a principle effector molecule
responsible for MSP-induced EMT in MDCK and
human cancer cells. Evidence also indicates that RSK2 is
responsible for TGF-b1-induced EMT.
Materials and methods
Cell Lines and Reagents
Martin-Darby canine kidney (MDCK) and human colon
cancer HT-29 cells were purchased from ATCC (Mana-
ssas, VA). MDCK cells stably expressing RON (M-RON)
were established as previously described [30]. Human
pancreatic cancer L3.6pl cells were provided by Dr. G.
E. Gallick (University of Texas M.D. Anderson Cancer
Center, Houston, TX). Human MSP was provided by
Dr. E. J. Leonard (National Cancer Institute, Bethesda,
MD). Human transforming growth factor (TGF)-b1 was
from R&D (Minneapolis, MN). Mouse monoclonal anti-
bodies (mAb, clone Zt/g4) and rabbit IgG antibody
(R5029) were used as previously described [32]. Mouse
mAb specific to phospho-tyrosine (PY-100), phospho-
Erk1/2, and other signaling proteins were from Cell
Signaling (Danvers, MA). Mouse, rabbit, or goat IgG
antibodies specific to panRSK, RSK1, RSK2, Snail,
E-cadherin, vimentin, claudin-1, and F-actin were from
BD Transduction Laboratories (Lexington, KY).
PD98059 (PD), wortmannin (WT), U0126, SB203580,
SB431524, rapamycin, and SL0101 were from CalBio-
chem (San Diego, CA). Small molecule inhibitor Com-
pound-1 (CP-1) specific to human RON [33] was from
Amgen (Thousand Oak, CA). SP600125, S31-201, XAV-
939, vismodegib, and SB431542 were from Selleck Che-
micals (Houston, TX), and Cay10512 was from Cayman
Chemicals (Ann Arbor, MI).
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Transient expression of human RSK1 or RSK2 in HT-29
cells
Transfection of cells with pcDNA3.1 containing RSK1
(pRSK1) or RSK2 cDNA (pRSK2) was performed using
Lipofectamine as previously described [32]. Briefly, cells
(1 × 106 cells in 60 mm diameter dish) were cultured
overnight and then transfected with 3 μg/dish of pRSK1
or pRSK2 vectors. The pRSK1/2 plasmids were provided
by Dr. J. Chen (Emory University School of Medicine,
Atlanta, GA). Cells transfected with an empty vector
pcDNA3.1 were used as control. Transfected cells were
incubated for 48 h and then processed for various biolo-
gical assays.
Immunoprecipitation and Western blot analysis
These methods were performed as previously described
[30]. Cellular proteins (250 μg/sample) were used for
immunoprecipitation by Zt/g4 (1 μg/sample) coupled to
protein G Sepharose beads. Individual proteins were
detected using specific antibodies in Western blot analy-
sis under reducing conditions. Membranes were
reprobed with rabbit IgG antibody to b-actin to ensure
equal sample loading [30].
Cellular immunofluorescent analysis
The method was performed as previously described [30].
To detect cytoplasmic or nuclear proteins, cells at 1 ×
104 cells per well in a 24-well plate were cultured over-
night and then stimulated for 24 h with MSP, TGF-b1
or both in the presence or absence of various small che-
mical inhibitors. Cells were fixed with cold acetone and
incubated with specific antibodies, followed by goat
anti-mouse IgG coupled with FITC. Normal mouse IgG
was used as the negative control. Cellular immunofluor-
escence was observed under Olympus BK71 microscope
equipped with fluorescent apparatus as previously
described [30].
Methods for silencing RSK1 or RSK2 mRNA expression in
L3.6pl cells
Synthetic siRNA specific to human RSK1 or RSK2 were
acquired from Dhamacon (Chicago, IL). To knockdown
RSK expression, L3.6pl cells were cultured overnight
and then transfected with RSK1 or RSK2 siRNA accord-
ing to the manufacturer’s instructions. After incubation
for 48 h, cells were washed and then processed for bio-
chemical and biological analyses.
Assays for cell morphological changes
The assays were performed as previously described [30].
M-RON or other cells (2 × 104/well in a 24-well plate)
were cultured overnight and then stimulated with or
without MSP (2 nM), TGF-b1 (5 ng/ml), or both at 37°
C for 24 h. Cell morphological changes were observed
and photographed using an Olympus BK71 inverted
microscope equipped with CCD camera. The length
of individual cells from experimental groups was
determined by measuring 200 cells and results were
expressed as elongation index and compared among var-
ious groups [30].
Cell migration assays
Wound healing assay was used to determine the ability
of cells to migrate and fill the open space as previously
described [32]. Cells were stimulated with MSP (2 nM),
TGF-b1 (5 ng/ml) or both for 16 or 24 h. The percen-
tage of open space filled by migrated cells was calculated
as previously described [32].
Results
Identification of RSK as an effector molecule in RON-
mediated EMT using cell-shape change based screen by
various small chemical inhibitors
MSP induces complete EMT in MDCK cells, featured
by spindle-like morphology, diminished E-cadherin
expression, appearance of mesenchymal marker vimen-
tin, and increased cell migration and invasiveness
[30,31]. However, the major signaling molecule(s) link-
ing RON signaling to these changes is unknown. To
identify these molecules, we performed a MSP-induced
cell-shape based screen using a panel of 12 small che-
mical inhibitors in M-RON cells. Intracellular proteins
representing 10 signaling pathways such as Erk1/2, PI-
3 kinase, b-catenin, Stat3, NF-B and others were tar-
geted. These signaling proteins are known to be
involved in cell morphological changes and motility
[30,34-37]. Cell elongation index measured from spin-
dle-like morphology was used to determine the effect
of individual inhibitors (Table 1). Prevention of MSP-
induced spindle-like morphology was not observed in
M-RON cells treated with wortmannin, SB203580,
SP600125, Cay10512, and S31-201, suggesting that sig-
naling from these pathways was not involved in MSP-
induced EMT. A moderate effect, based on changes in
elongation index, was seen when rapamycin, vismode-
gib, and XAV-939 were applied, suggesting that signal-
ing from Hedgehog, Wnt/b-catenin, and FRAP/mTOR
pathways played a role in MSP-induced EMT. As
expected, inhibition of RON and Erk1/2 signals by CP-
1 and PD98059, respectively, completely blocked the
effect of MSP, indicating the importance of the RON-
Erk1/2 pathway in regulating EMT phenotype. An
interesting result was the outcome of SL0101-mediated
effects, which completely prevented MSP-induced
EMT. SL0101 is a specific inhibitor of RSK and regu-
lates various cellular activities [38]. The observed
effects prompted us to determine if RSK is indeed a
critical determinant in RON-mediated EMT.
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MSP-induced RSK2 dissociation with Erk1/2 and its
phosphorylation in correlation with Erk1/2 activation
RSK isoforms such as RSK1 or RSK2 associate with
Erk1/2 in quiescent cells [21]. Dissociation between RSK
and Erk1/2 requires phosphorylation [21]. To determine
which RSK isoform(s) is regulated by MSP, M-RON
cells were stimulated in the presence or absence of
U0126, an inhibitor that blocks RSK dissociation with
Erk1/2 [39]. TGF-b1 was used as the control. RSK iso-
forms associated with Erk1/2 were determined by anti-
Erk1/2 mAb immunoprecipitation followed by Western
blot analysis using anti-RSK1 or RSK2 antibody. As
shown in Figure 1A, RSK2 but not RSK1 was sponta-
neously associated with Erk1/2 in M-RON cells cultured
in DMEM containing 1% FBS. In contrast, interaction
between RSK1 and Erk1/2 was not observed. It should
be pointed out that RSK1 was expressed in M-RON
cells (data not shown); however, Erk1/2 was not
detected in anti-RSK1 immunoprecipitation. After MSP
stimulation, RSK2-Erk1/2 complex dissociated. TGF-1b
also induced RSK2-Erk1/2 dissociation although its
effect was moderate. However, in cells treated with
U0126, MSP or MSP plus TGF-b1-induced dissociation
of RSK2-Erk1/2 complex was blocked. Similar results
were observed when immunoprecipitation was per-
formed using anti-RSK2 mAb (data not shown). Taken
together, these results suggested that MSP is capable of
regulating RSK2 interaction with Erk1/2 and TGF-b1
exerts a similar effect. MSP-induced dissociation could
be the first step in regulating RSK2 activity.
The next experiment determined whether MSP acti-
vates RSK2 in association with Erk1/2 phosphorylation.
Again, TGF-b1 was used for comparison. Results in
Figure 1B showed the time-dependent RSK2 phosphory-
lation at Ser380 residue. MSP acted as a strong inducer
of RSK2 phosphorylation, in which high levels of RSK2
phosphorylation were maintained for up to 30 min and
then gradually reduced. The effect of TGF-b1 on RSK2
phosphorylation was relatively weak, which peaked at
about 5 min and then gradually diminished. In com-
bined stimulation, TGF-b1 significantly potentiated
MSP-induced RSK2 phosphorylation. In this case, RSK2
phosphorylation was prolonged up to 60 min, a signifi-
cant increase compared to those stimulated by MSP or
TGF-b1alone.
To correlate RSK2 phosphorylation with Erk1/2 acti-
vation, we determined MSP or TGF-b1-induced Erk1/2
phosphorylation. Results in Figure 1C showed that MSP
strongly induced Erk1/2 phosphorylation at Tyr 202/204
residues. Significant Erk1/2 phosphorylation was seen as
early as 5 min, peaked at 15 min, and then gradually
reduced to the baseline at 240 min (4 h). Such a time-
dependent kinetic effect correlated well with the time
course of RSK2 phosphorylation (Figure 1B). In contrast,
TGF-b1-induced Erk1/2 phosphorylation occurred at
relatively later stages and had a delayed time course.
The curve did not seem to correlate with the time
course of RSK2 phosphorylation (Figure 1B). Again,
TGF-b1 potentiated MSP-induced Erk1/2 phospho-
rylation. A strong and long-lasting effect on Erk1/2
phosphorylation was achieved when both stimuli were
used (Figure 1C). These results, together with those
shown in Figure 1B, demonstrated that MSP is a strong
inducer of RSK2 phosphorylation. The kinetics of
Table 1 Effect of Various Small Chemical Inhibitors on MSP-Induced Spindle-Like Morphologies in RON-Expressing
MDCK cells*
Small molecule inhibitors Signal proteins inhibited Amount used to treat cells Cell elongation index Preventive effect (%)
Control N/A N/A 1.0 ± 0.24 None
MSP none 2.0 nM 3.12 ± 0.47 N.D
CP-1 RON 100 μM 1.05 ± 0.26 98.4%
PD98059 MEK1/2 100 μM 1.03 ± 0.31 97.1%
Wortmannin PI-3 kinase 50 μM 2.9 ± 0.41 7.1%
SB203580 p38 MAP kinase 50 μM 3.1 ± 4.6 0.6%
SP600125 JNK1,2,3 5 μM 3.07 ± 0.39 1.6%
Cay10512 NF-B 5 μM 2.03 ± 0.33 39.4%
S31-201 Stat3 10 μM 1.25 ± 0.34 59.9%
XAV-939 Wnt/b-catenin 5 μM 2.16 ± 0.32 30.8%
SL0101 RSK 50 μM 1.09 ± 0.27 97.1%
Rapamycin FRAP/mTOR 100 nM 2.69 ± 0.25 13.8%
Vismodegib Hedgehog 1 μM 2.04 ± 0.22 34.6%
SB431542 TGF-b1 receptor 1 μM 2.97 ± 0.24 4.8%
*M-RON cells (1 × 104 cells/well) in DMEM containing 1% FBS were stimulated with 2 nM of MSP in the presence of absence of individual small chemical
inhibitors for 24 h. Cell morphological changes were observed under microscope and photographed with CCD camera. Cell elongation index (CEI) was
determined by measuring the length of individual adherent cells among various groups. CEI from control cells was set as one. The percentages of preventive
effect were calculated by comparing with as the CEI from MSP-treated cells previously described [45]
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phosphorylation between Erk1/2 and RSK2 correlated
well upon MSP stimulation. TGF-b1 showed a moderate
stimulating effect on RSK2 phosphorylation. It induced
Erk1/2 phosphorylation but showed a relatively delayed
time-course. However, TGF-b1 potentiated MSP-
induced RSK2 and Erk1/2 phosphorylation.
Prevention of MSP-induced RSK2 activation by small
chemical inhibitors specific to RON and Erk1/2
To determine if MSP-induced RSK2 phosphorylation is
indeed mediated by RON and Erk1/2 signaling, M-RON
cells were stimulated in the presence or absence of spe-
cific RON inhibitor CP-1 and Erk1/2 inhibitor PD98059.
RSK2 phosphorylation was determined by Western blot
analysis. CP-1 inhibited MSP-induced RON phosphory-
lation in a dose-dependent manner (Figure 2A). CP-1
treatment also led to diminished Erk1/2 phosphoryla-
tion. Significantly, CP-1 inhibited MSP-induced RSK2
phosphorylation in a dose-dependent manner. We also
observed the inhibitory effect of CP-1 in cells stimulated
with MSP plus TGF-b1. However, levels of inhibition, as
shown by the phosphorylation levels of Erk1/2 and
RSK2, were not as strong as those shown in cells stimu-
lated with MSP alone. Dramatic inhibition was only
seen when high concentrations of CP-1 (up to 300 μg/
ml) were used. Results from PD98059 experiments con-
firmed that inhibition of Erk1/2 had no effect on MSP-
induced RON phosphorylation. However, levels of Erk1/
2 phosphorylation were diminished by PD98059 in
a dose-dependent manner (Figure 2B). Moreover,
PD98059 inhibited MSP or MSP plus TGF-b1-induced
RSK2 phosphorylation in a dose-dependent manner.
Thus, the results in Figure 2 demonstrated that by inhi-
biting RON or Erk1/2 activation, both CP-1 and
PD98059 are able to prevent MSP or MSP plus TGF-
b1-induced RSK2 phosphorylation, suggesting that
activated RON and Erk1/2 signaling is required for
MSP-induced RSK2 phosphorylation.
Figure 1 MSP-induced RSK2 dissociation with Erk1/2 and their phosphorylation in M-RON cells. A) MSP-induced dissociation of RSK2
from Erk1/2 in intact cells: M-RON cells (3 × 106 cells/dish) were incubated in DMEM containing 1% FBS overnight and then stimulated for 30
min with MSP (2 nM), TGF-b1 (5 ng/ml), or both in the presence or absence of 5 μM of U0126. Cellular proteins (250 μg/sample) from cell
lysates were subjected to immunoprecipitation with rabbit IgG antibody specific to Erk1/2. Proteins in anti-Erk1/2 immunocomplex were
subjected to Western blot analysis using antibodies specific to RSK1 or RSK2. Membranes were also reprobed with IgG antibody to Erk1/2 as the
loading control. B) and C) MSP-induced RSK2 phosphorylation and its correlation with Erk1/2 activation: M-RON cells (3 × 106 cells/dish) in
DMEM with 1% FBS were stimulated with MSP, TGF-b1, or both for various times. Cellular proteins (50 μg/sample) from cell lysates were
subjected to Western blot analysis. Phosphorylation of RSK2 and Erk1/2 was detected by individual antibodies specific to phospho-RSK2 Ser380
or Erk1/2 T202/204, respectively. RSK2 and Erk1/2 detected by their corresponding regular antibodies were used as the loading control.
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Effect of MSP on RSK2 nuclear translocation and
phosphorylation
To further determine the effect of MSP on RSK2, we
studied RSK2 nuclear translocation in comparison with
Erk1/2 activation. Cells were stimulated by MSP or MSP
plus TGF-b1 for various times and cytoplasmic and
nuclear proteins were prepared. RSK2 was mainly
detected in cytoplasmic fraction in non-stimulated
M-RON cells. A small amount of RSK2 was also present
in nuclear proteins (Figure 3A). This pattern was similar
to that of Erk1/2, in which Erk1/2 in both cytoplasmic
and nuclear fractions was observed. Upon MSP stimula-
tion, the amounts of RSK in nuclear fraction were
dramatically increased in a time-dependent manner.
Phosphorylation was observed not only in cytosolic but
also in nuclear RSK2. Again, a similar pattern was
Figure 2 Inhibitory effect of CP-1 and PD98059 on MSP or MSP plus TGF-b1-induced RSK2 phosphorylation: M-RON cells (3 × 106 cells
per dish) in DMEM with 1% of FBS were first treated with CP-1 or PD98059 for 10 min followed by stimulation with MSP (2 nM) or MSP plus
TGF-b1 (5 ng/ml). Cells were collected 30 min after stimulation. Phosphorylated RON was determined by Western blot analysis after Zt/g4
immunoprecipitation of cell lysates (250 μg proteins/sample). Phosphorylated Erk1/2 and RSK2 were directly determined by Western blot analysis
using specific antibodies, respectively. Membranes were also reprobed with individual antibodies to detect non-phosphorylated proteins as the
loading controls. Data shown here are from one of two experiments with similar results.
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documented for Erk1/2, in which phosphorylated Erk1/2
was detected in nuclear proteins. Results in Figure 3B
demonstrated that MSP in combination with TGF-b1
induced RSK2 nuclear translocation and phosphoryla-
tion. This effect was accompanied by Erk1/2 phosphory-
lation. A major difference was that the time course for
both RSK2 and Erk1/2 phosphorylation lasted longer in
MSP and TGF-b1 co-stimulated cells than in cell treated
with MSP alone.
We further validated results from Western blotting by
studying cellular RSK and Erk1/2 distribution using
DSU confocal microscope image analysis. Cytoplasmic
and nuclear RSK2 and Erk1/2 were detected by anti-
RSK2 or Erk1/2 immunofluorescent analysis. As shown
in Figure 3C, RSK2 immunofluorescent staining was
detected in both cytoplasmic and nuclear compartments
in control M-RON cells. Upon MSP stimulation,
increased nuclear fluorescent intensity was observed,
indicating nuclear accumulation of RSK2 and Erk1/2.
We noticed that RSK2 nuclear staining appeared as a
pattern of condensed granules. Cellular distribution of
Erk1/2 in control cells was similar to that of RSK2. MSP
induced Erk1/2 nuclear translocation with increased
nuclear fluorescent intensity. The patterns of Erk1/2
nuclear staining were in a relatively diffused manner.
Consistent with these observations, RSK 2 nuclear accu-
mulation also was observed in cells stimulated with
MSP plus TGF-b1 with granule-like staining pattern.
Again, Erk1/2 accumulated in nucleus with combined
stimulation but distributed in a more diffused pattern.
These results, together with those in Figure 3A and 3B,
demonstrated that distribution and phosphorylation
between RSK2 and Erk1/2 upon MSP stimulation exist.
Preventive effect of RSK2 inhibitor SL0101 on MSP or
MSP plus TGF-b1-induced EMT
To determine if RSK2 is indeed an effector molecule, we
studied the effect of SL0101 on MSP-induced EMT. We
also used TGF-b1 to induce EMT for evaluation. Results
in Figure 4A showed that MSP induced spindle-like
morphological changes in M-RON cells. As expected,
this effect was prevented by CP-1 and PD98059, but not
by PI-3 kinase inhibitor wortmannin. Consistent with
results shown in Table 1, SL0101 significantly prevented
Figure 3 Effect of MSP on RSK2 phosphorylation and its nuclear translocation: M-RON cells (3 × 106 cells per dish) in DMEM with 1% FBS
were stimulated with MSP (2 nM), TGF-b1 (5 ng/ml), or MSP plus TGF-b1 for various times. Cellular proteins (50 μg/sample) from cell lysates
were subjected to Western blot analysis using antibodies specific to regular or phospho-RSK (Ser380) and Erk1/2. A) MSP induced RSK2
phosphorylation and nuclear translocation. B) Effect of MSP and TGF-b1 on RSK2 phosphorylation and nuclear translocation. C)
Immunofluorescent analysis of MSP or MSP plus TGF-b1-induced RSK2 nuclear translocation. M-RON cells were stimulated with MSP or MSP plus
TGF-b1v for various times. Cells were fixed with cold acetone, blocked with 1% BSA, followed by incubation with antibody specific to RSK2. FITC
coupled rabbit anti-mouse IgG was used as the detecting antibody. Immunofluorescence was observed by Olympus BT71 microscope equipped
with fluorescent apparatus as previously described [45]. Scale bars represent 5 μm.
Ma et al. Molecular Cancer 2011, 10:66
http://www.molecular-cancer.com/content/10/1/66
Page 7 of 15
MSP-induced spindle-like morphology. SL0101 also pre-
vented TGF-b1-induced cell shape changes, but its effect
was not complete. Moreover, the synergistic effect of
MSP and TGF-b1 in cell morphology was affected by
SL0101 (Figure 4A). In all these cases, altered cell mor-
phology was significantly restored to original epithelial
appearance.
Experiments were then conducted to determine if
SL0101 regulates E-cadherin, claudin-1, and vimentin
expression (Figure 4B). CP-1, PD98059, and wortmannin
were included as controls. SL0101 completely prevented
MSP-induced reduction of E-cadherin. Sl0101 also pre-
vented increased vimentin expression. These observa-
tions concurred with results from cells treated with CP-
1 and PD98059, but not with wortmannin, Additionally,
SL0101 treatment restored claudin-1 expression, a pro-
tein essential for epithelial tight junction formation [40].
Preventive effect of SL0101 also was seen in M-RON
cells stimulated with TGF-b1 and MSP plus TGF-b1. In
both cases, expression of E-cadherin and claudin-1 was
restored and induction of vimentin was blocked.
Activation of transcription repressor Snail is known to
suppress E-cadherin expression leading to EMT [16,41].
Analysis of nuclear proteins from MSP-treated M-RON
cells by Western blotting revealed that inhibition of RSK2
by SL0101 had a negative effect on RON-mediated Snail
expression (Figure 4C). SL0101 prevented MSP-induced
Snail expression in M-RON cells. Reduced Snail expres-
sion was also seen in MSP-stimulated cells treated with
CP-1 and PD98059. Again, the action of SL0101 was
not limited to MSP, as SL0101 also prevented TGF-
b1-induced Snail expression. We want to emphasize that
Snail expression induced by TGF-b1 was sensitive to
PD98059 but not to CP-1 (Figure 4C).
Figure 4 Preventive Effect of RSK inhibitor SL0101 on MSP and MSP plus TGF-b1-induced EMT: M-RON cells (1 × 105 cells/well in a 24-
well plate) were incubated overnight and then stimulated with MSP (2 nM), TGF-b1 (5 ng/ml), or both at 37°C for 24 h. Small chemical
inhibitors specific to RON (CP-1, 100 nM), Erk1/2 (PD98059, 100 μM), PI-3kinase (wortmannin, 50 μM), and RSK (SL0101, 50 μM) were added
simultaneously. A) Cell morphological changes were observed and photographed using Olympus BK71 microscope equipped with CCD camera.
Scale bars represent 20 μm. B) Cellular proteins (50 μg per sample) were also prepared for Western blot analysis. Expression of E-cadherin,
claudin-1, and vimentin was determined by using specific antibodies. Membranes were also reprobed with antibodies to actin as the loading
control. C) Transcription repressor Snail in nuclear proteins was detected by Western blot analysis using anti-Snail antibody. Preparation of
nuclear factions was performed as previously described [45]. D) and E) b-catenin redistribution and F-actin reorganization was determined by
immunofluorescent analysis [35] using antibodies specific to b-catenin and F-actin, respectively. Data shown here are from one of three
experiments with similar results. Scale bars represent 10 μm.
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We further studied the effect of SL0101 on MSP and
TGF-b1-induced redistribution of b-catenin and F-actin.
Both proteins play a role in RON-mediated EMT
[30,35]. Results in Figure 4D showed the redistribution
of b-catenin from cell membrane to cytoplasmic com-
partment upon MSP and TGF-b1 stimulation. SL0101
prevented MSP and TGF-b1-induced b-catenin redistri-
bution and cytoplasm-associated b-catenin disappeared
after addition of SL0101. A similar effect also was
observed in cells treated with PD98059. In both cases,
b-catenin was redistributed to cell membrane along with
typical epithelial morphology. The effect of SL0101 on
F-actin distribution was very similar to those of b-cate-
nin after treatment with MSP, TGF-b1, and both (Figure
4E). F-actin was mainly associated with cell membrane
with a certain amount of cytoplasmic distribution. MSP
and TGF-b1 caused increased accumulation of F-actin
in cytoplasm. This effect was prevented by SL0101,
which restored F-actin distribution to its original
membrane-associated appearance. This effect was
also accompanied by the reappearance of epithelial
morphology.
We performed the wound-healing assay to determine
if SL0101 can prevent MSP-induced migration of M-
RON cells. Increased migration is a function associated
with EMT. Results in Figure 5 showed that M-RON
cells had spontaneous migration (35.0%) and MSP sti-
mulation further enhanced cell motility (86.0%).
Treatment of cells with SL0101 alone had no effect on
cell migration; however, SL0101 significantly prevented
MSP or MSP-plus TGF-b1-induced cell migration. The
percentages of cell migration induced by MSP and MSP
plus TGF-b1 (86.0% and 89.3%, respectively) were dra-
matically reduced after SL0101 treatment (38.4% and
45.2%, respectively). We observed inhibition levels that
were comparable to those treated with CP-1 and
PD98059. Thus, results in Figure 4 and 5 demonstrated
that SL0101 inhibition of RSK prevented MSP and
TGF-b1-induced spindle-like morphology accompanied
with redistribution of b-catenin and F-actin. E-cadherin
and claudin-1 expression reappeared and vimentin
expression was blocked. These activities were associated
with the inhibition of transcription repressor Snail
expression. Moreover, SL0101 significantly impairs MSP
and TGF-b1 induced cell migration, which is a function
associated with EMT.
Effect of increased RSK expression in MSP-induced
EMT-like activity in cancer cells
To study the effect of RSK2 on MSP-induced EMT in
more detail, two human cancer cell lines L3.6pl and
HT-29 were selected based on their differences in RSK1
and RSK2 levels and similarities in RON and TGF-b
receptor expression (Figure 6A). Pancreatic cancer
L3.6pL cells expressed regular levels of RSK1 and RSK2.
MSP and TGF-b1 stimulation caused elongated cell
Figure 5 Effect of SL0101 on MSP or MSP plus TGF-b1-induced cell migration. The monolayer of M-RON cells in DMEM with 1% FBS) were
wounded with a plastic tip and then stimulated with MSP (2 nM), TGF-b1 (5 ng/ml), or both in the presence or absence of CP-1 (300 μg/ml),
PD98059 (100 μM), and SL0101 (50 μM). After incubation for 16 h, cells that migrated into the open spaces were observed under microscope
and photographed. Wounded areas that covered by migrated cells were calculated as previously described [35]. Data shown here are from one
of two experiments with similar results. Scale bars represent 50 μm.
Ma et al. Molecular Cancer 2011, 10:66
http://www.molecular-cancer.com/content/10/1/66
Page 9 of 15
morphology, reduced E-cadherin expression, and
increased vimentin expression (Figure 6B). Combined
MSP and TGF-b1 treatment further enhanced the mod-
ulating effect on E-cadherin and vimentin expression.
These results indicated that L3.6pl cells show EMT-like
phenotypic changes after MSP and TGF-b1 stimulation
and a synergistic activity between RON and TGF-bRI/II
signaling in induction of EMT-like phenotype.
HT-29 cells expressed extremely low levels of RSK1
and RSK2 (Figure 6A). Treatment of cells with MSP,
TGF-b1 or both caused barely any morphological
changes (data not shown). Western blot analysis also
failed to observe any changes in E-cadherin and
vimentin expression in MSP plus TGF-b1-stimulated
HT-29 cells (data not shown). However, RSK2 overex-
pression by pRSK2 plasmid transfection resulted in cell
morphological changes after MSP stimulation (Figure
6C). We observed similar changes when transfected HT-
29 cells were stimulated with TGF-b1 or MSP plus
TGF-b1. Analysis of E-cadherin and vimentin expression
in pRSK2-transfected HT-29 cells confirmed that MSP
and TGF-b1 stimulation caused E-cadherin reduction
and vimentin induction (Figure 6D). These results sug-
gested that increasing RSK2 expression renders HT-29
cells responsive to MSP and TGF-b1-induced EMT-like
activities.
Figure 6 Requirement of RSK2 expression in MSP and TGF-b1 induced EMT-like activity in cancer cells. A) Expression of RON, RSK1, RSK2,
and TGF-b receptors in human cancer L3.6pl and HT-29 cells. Cell lysates (50 μg/sample) were subjected to Western blot analysis using
antibodies specific to individual proteins. B) MSP induces EMT-like activities in pancreatic cancer L3.6pl cells. L3.6pl cells (0.5 × 106 cells per dish)
were cultured overnight and then stimulated at 37°C with MSP (2 nM), TGF-b1 (5 ng/ml), or both for 24 h. Cell morphological changes were
observed by Olympus microscope and photographed with CCD camera. E-cadherin and vimentin expression was determined by Western blot
analysis using cell lysates as described previously [35]. Actin was used as the loading control. Scale bars represent 20 μm. C) Forced RSK2
expression facilitates MSP and TGF-1-induced EMT-like activity in HT-29 cells. Cells (2 × 106 cells per dish) were transiently transfected with 3 μg
of pRKS2 plasmid or control vector pcDNA3.1 for 48 h and then stimulated with MSP and TGF-b1 as described above. Morphological changes
and expression of individual proteins were determined as described in A. Scale bars represent 20 μM. D) RSK2 expression diminishes E-cadherin
expression and increases vimentin expression. HT-29 cells were transiently transfected with pRSK2 plasmid for 48 h followed by stimulation with
MSP, TGF-b1 or both for 24 h. Cell lysates were subjected to Western blot analysis using antibodies specific to E-cadherin or vimentin. b-actin
was used as the loading control. Data shown here are from one of two experiments with similar results.
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Effect of RSK specific siRNA on MSP-induced cell
migration
To further confirm the role of RSK2, we transiently
transfected L3.6pl cells with specific siRNA to silence
RSK1 or RSK2 mRNA expression. Results in Figure 7A
showed that siRNA specific to RSK1 effectively silenced
RSK1 expression but had no effect on RSK2 expression.
RSK2 specific siRNA only silenced RSK2 expression but
had no effect on RSK1 expression. These results con-
firmed specificities of siRNA used to silence RSK1 and
RSK2, respectively. Analysis of MSP and TGF-b1-regu-
lated epithelial and mesenchymal proteins revealed that
silencing RSK1 expression did not prevent MSP and
TGF-b1-induced reduction of E-cadherin and induction
of vimentin. In contrast, knockdown of RSK2 expression
restored E-cadherin expression and prevented vimentin
induction. We also observed these effects in cells treated
with TGF-b1 and MSP plus TGf-b1, indicating that
RSK2 was required for MSP and TGF-b1-induced EMT-
like biochemical changes.
We further studied the effect of siRNA mediated
RSK2 knockdown on cell migration by the wound heal-
ing assay (Figure 7B). L3.6pl cells showed spontaneous
migration, which was further enhanced by MSP stimula-
tion. The amount of open space covered by migrated
cells increased from 34% up to 86%. Knockdown of
RSK1 had little effect on spontaneous cell migration,
but silencing RSK2 expression showed a moderate effect
Figure 7 Effect of siRNA-mediated RSK2 knockdown on MSP and TGF-b1-induced EMT-like activities and cell migration by L3.6pl cells:
A) Knockdown of RSK2 expression by specific siRNA restored E-cadherin expression and prevented vimentin induction. L3.6pl cells (2 × 106 cells
per dish) were cultured overnight and transiently transfected with 3 μg/dish of pcDNA3.1, pRSK1, or pRSK2 by using lipofectamine (Invitrogen).
Transfected cells were cultured for 72 h and then lysed with lysis buffer. Cellular proteins (50 μg per sample) were subjected to Western blot
analysis as described previously using antibodies specific to RSK1, RSK2, E-cadherin, and vimentin, respectively. The membranes were also
reprobed with rabbit IgG to actin as the loading control. B) L3.6pl cells were transiently transfected with pcRSK1 or pcRSK2 for 48 h followed by
stimulation with MSP, TGF-b1, or both as described above. The wound healing assay was performed after a 24 h-incubation to determine the
levels of cell migration. The percentage of wounded area covered by migrated cells was determined as previously described [45]. Data shown
here are from one of three experiments with similar results. Scale bars represent 50 μm.
Ma et al. Molecular Cancer 2011, 10:66
http://www.molecular-cancer.com/content/10/1/66
Page 11 of 15
on spontaneous cell migration. In MSP-induced cell
migration, silencing RSK1 expression did not impair
MSP-induced cell migration, as more than 80% of the
open space was still covered by migrated cells. In con-
trast, MSP-induced cell migration was significantly
impaired in RSK2 siRNA treated cells. In this case, only
27% of the open space was covered by migrated cells,
which was similar to spontaneous migration. TGF-b1-
induced cell migration was not affected by knockdown
of RSK1. The inhibitory effect was only observed in cells
treated with specific RSK2 siRNA. Moreover, we
observed that silencing RSK2 expression also impairs
cell migration synergized by combined MSP and TGF-
b1 stimulation. Thus, silencing RSK2 but not RSK1 by
specific siRNA decreases MSP-induced cell migration in
L3.6pl cancer cells.
Discussion
The purpose of this study is to identify the major signal-
ing molecule(s) that controls MSP-induced EMT in
epithelial cells. Altered RON expression and activation
contribute to malignant progression of various epithelial
cancers [30,42]. RON is overexpressed in various types
of primary cancer samples including those from colon,
breast, and pancreas [42]. Aberrant RON activation also
causes increased tumor cell proliferation, matrix inva-
sion, and drug resistance [42]. Currently, the role of
MSP and RON in regulating EMT under physiological
conditions is largely unknown. In contrast, MSP-induced
RON activation or RON overexpression have been
shown to induce EMT in various cancer cells including
colon, breast, and pancreas [30,31,43-45]. The changes
to mesenchymal phenotype in RON-activated tumor
cells have been considered as a molecular basis for
increased tumor malignancy including cell migration,
matrix invasion, and distance metastasis [42]. Several
upstream signaling proteins such as Erk1/2 have been
implicated in MSP-induced EMT [30,31]; however, the
major effector molecule(s) that transduces RON signals
leading to EMT is still unknown. Intracellular proteins
such as b-catenin and NF-B have been identified as
effector molecules in MSP-induced EMT [45-47].
Nevertheless, their significance is often limited to parti-
cular cell models. Thus, identification of the major sig-
naling molecule(s) is important not only for an
understanding of the cellular mechanisms of EMT, but
also for the development of potential therapies that tar-
get cancer cell migration and invasion.
Results from this study indicate that RSK2 is a major
determinant bridging RON signaling to EMT. This con-
clusion is supported by the following evidence. First,
inhibition of RSK, as indicated in the cell-shape based
screen by using specific RSK inhibitor SL0101, comple-
tely prevented MSP-induced spindle-like morphology.
Inhibitors that target other proteins such as NF-B,
Stat3, and hedgehog, except CP-1 and PD98059, only
showed moderate effect. This indicates that RSK activa-
tion is essential in MSP-induced spindle-like morphol-
ogy. Second, MSP-induced RON activation dissociated
RSK2 from Erk1/2, and caused RSK2 phosphorylation
and subsequent nuclear translocation. These data sug-
gest that MSP is a strong RSK activation inducer, which
is mediated by RON transduced signals. Third, RSK2
phosphorylation relied on the RON-Erk1/2 pathways.
Inhibition of RON or Erk1/2 by their corresponding
small chemical inhibitors prevented MSP-induced RSK2
phosphorylation. These data also established that RSK is
a downstream molecule in the MSP-RON-Erk1/2 axis.
Fourth, inhibition of RSK2 by SL0101 blocked MSP-
induced spindle-like changes, which is evident by the
redistribution of b-catenin to the membrane and reorga-
nization of f-actin to original epithelial morphology.
Moreover, in SL0101 treated cells, epithelial morphology
was completely restored with re-expression of E-cad-
herin and claudin-1, reduction of vimentin expression,
and minimized transcription repressor Snail expression.
Fifth, SL0101 prevention of RSK2 activation decreased
MSP and TGF-b1-induced cell migration. As shown in
the wound healing assay, RON-mediated cell migration
was dramatically reduced upon inhibition of RSK2 by
SL0101. Finally, RSK2 overexpression led to EMT-like
phenotypes in colon HT-29 cancer cells that express
extremely low levels of RSK2. Moreover, specific siRNA-
mediated RSK2 knockdown prevented MSP and TGF-
b1-induced EMT-like activity in pancreatic cancer
L3.6pl cells. Considering these factors, we concluded
that SRK2 is the major effector molecule in RON-
mediated EMT.
In reviewing cellular mechanisms underlying EMT in
different types of epithelial and cancerous cells, it is
apparent that various proteins belonging to multiple sig-
naling pathways are involved in regulating EMT [4,5].
The identified proteins include Erk1/2, PI-3 kinase,
AKT, p38, b-catenin, NF-B, Stat3, Smad, and others
[11-20]. The typical example is the Erk1/2-mediated sig-
naling event that leads to EMT [17,22]. Specifically,
Erk2 but not Erk1 has been found to be critical in EMT
induction, which is mediated by DEF motif-dependent
signaling events [17]. Currently, the signaling proteins
participated in EMT represent at least seven different
signaling pathways. The involvement of such diverse
signaling proteins suggests the possible existence of a
central signaling molecule that acts as a switch for
initiation of EMT in epithelial cells. In supporting this
notion, recent studies has shown that RSK acts as a
principal effector molecule in coordinating cellular EMT
program in epithelial cells [22]. Genome-wide RNAi
screen also has discovered that multiple proteins in a
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broad range of pathways depend on RSK for induction
of cellular migration program [23]. We observed that
RSK2 activation is critical in controlling EMT in MDCK
and cancer cells mediated by MSP. Moreover, RSK2 is
also required for TGF-b1-induced EMT. The involve-
ment of RSK2 in two different signaling pathways sug-
gests that RSK2 acts as a potential central molecule in
regulating EMT and cell migration. In other words,
RSK2 activation acts as the convergent point for both
RON-Erk1/2 and TGF-b receptor I/II-Smad pathways
leading to complete EMT.
The importance of RSK2 in RON signaling also estab-
lishes a critical link to other signaling molecules
observed in MSP-induced EMT and cell migration. Acti-
vation of Erk1/2 is required for MSP-induced EMT
[30,31]. As a downstream molecule of the Erk1/2 path-
way, RSK2 transduces MSP-induced and Erk1/2
mediated signal for EMT as demonstrated in this study.
In breast cancer cells, NF-B activation is implicated in
RON-mediated cellular motility [47]. RSK is known to
activate NF-B by phosphorylating NF-B inhibitor
IBa and inducing its degradation [48]. This finding
suggests that the observed NF-B activity in MSP-sti-
mulated breast cancer cells could be channeled through
RON-activated RSK2. In colon cancer cells stimulated
by MSP, increased b-catenin accumulation contributes
to spindle-like morphologies with increased migration
[35]. RSK2 activation is known to increase steady-state
of b-catenin through phosphorylation and inhibition of
a b-catenin regulator GSK-3b [49]. These activities
imply that the RON-mediated inhibition of GSK-3b [35]
could be caused by MSP-induced RSK2 activation. The
role of MSP-activated AKT activity in cell migration is
another example [34]. Currently, evidence of direct RSK
activation by AKT is not available. In contrast, studies
have indicated that RSK is a mediator of growth factor-
induced activation of PI-3 kinase and AKT in epithelial
cells [50]. Thus, it is likely that MSP-induced AKT acti-
vation is mediated by RSK. Such activation facilitates
AKT in regulating MSP-induced cell migration. Consid-
ering all these facts, we reasoned that RSK is centered
in MSP-induced and RON-mediated EMT with
increased cell migration.
Studies sing pancreatic L3.6pl and colon HT-29 cells
provide additional evidence showing the importance of
RSK2 in MSP-induced EMT-like activity. First, we con-
firmed results derived from the MDCK cell model and
demonstrated that RSK2 but not RSK1 is selectively
involved in regulating RON-mediated EMT and asso-
ciated cell migration. In the L3.6pl cell model, only
RSK2 specific siRNA prevented MSP-induced EMT and
cell migration. Second, we demonstrated that MSP-
induced EMT-like phenotype is dependent on RSK2
expression and activation. In L3.6pl cells that express
regular levels of RSK1 and RSK2, MSP induces EMT-
like phenotypes featured by elongated cell morphology,
reduced E-cadherin expression, and increased vimentin
expression (Figure 6). In contrast, these activities were
not observed in HT-29 cells that express minimal levels
of RSK1 and RSK2. HT-29 cells express both RON and
oncogenic variant RON160 and both regulate HT-29
cell growth [51]. However, MSP fails to induce EMT
and migration in HT-29 cells, which provides indirect
evidence indicating the role of RSK2 in MSP-induced
EMT and cell migration. Rescue experiments by pRSK2
cDNA transfection confirmed this theory. As shown in
Figure 6C, RSK2-transfected HT-29 cells underwent
spindle-like morphological changes with diminished E-
cadherin and increased vimentin expression. Additional
evidence supporting this notion comes from studies
using RSK2-specific siRNA. Knockdown of RSK2
expression significantly inhibited MSP-induced L3.6pl
cell migration (Figure 7), which reaffirms the impor-
tance of RSK2 in MSP-induced EMT. The final observa-
tion is that the effect of RSK2 on EMT is not limited to
MSP. TGF-b1-induced EMT and cell migration also
were affected by inhibition of RSK2. HT-29 cells with
minimal RSK2 expression did not respond to TGF-b1.
Spindle-like morphology was only seen when RSK2 is
overexpressed. Western blot analysis of E-cadherin and
vimentin expression in RSK2 deficient and transfected
HT-29 cells confirmed that this is the case. RSK2 siRNA
based analysis of cell migration further demonstrated
that knockdown of RSK2 expression significantly
impairs TGF-b1-induced L3.6pl cell migration.
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